...
search icon
asnd-img

Ascendis Pharma AS, Common Stock

ASND

NSQ

$164.15

+$3.7

(2.31%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$9.69B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
560.21K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.54
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$111.09 L
$169.37 H
$164.15

About Ascendis Pharma AS, Common Stock

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameASNDSectorS&P500
1-Week Return1.86%3.64%6.36%
1-Month Return1.93%-5.42%-5.32%
3-Month Return30.23%-6.89%-8.86%
6-Month Return25.96%-7.54%-5.61%
1-Year Return19.88%-1.81%8.61%
3-Year Return51.58%2.1%27.58%
5-Year Return23.93%35.25%90.38%
10-Year Return733.25%88.1%160.03%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue6.95M7.78M51.17M266.72M363.64M[{"date":"2020-12-31","value":1.91,"profit":true},{"date":"2021-12-31","value":2.14,"profit":true},{"date":"2022-12-31","value":14.07,"profit":true},{"date":"2023-12-31","value":73.35,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue-3.52M12.14M44.40M44.26M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":7.94,"profit":true},{"date":"2022-12-31","value":27.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.69,"profit":true}]
Gross Profit6.95M4.25M39.04M222.32M319.38M[{"date":"2020-12-31","value":2.18,"profit":true},{"date":"2021-12-31","value":1.33,"profit":true},{"date":"2022-12-31","value":12.22,"profit":true},{"date":"2023-12-31","value":69.61,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%54.71%76.28%83.36%87.83%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":54.71,"profit":true},{"date":"2022-12-31","value":76.28,"profit":true},{"date":"2023-12-31","value":83.36,"profit":true},{"date":"2024-12-31","value":87.83,"profit":true}]
Operating Expenses337.57M456.05M600.85M677.86M598.15M[{"date":"2020-12-31","value":49.8,"profit":true},{"date":"2021-12-31","value":67.28,"profit":true},{"date":"2022-12-31","value":88.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":88.24,"profit":true}]
Operating Income(330.62M)(451.79M)(561.81M)(455.54M)(278.76M)[{"date":"2020-12-31","value":-33062000000,"profit":false},{"date":"2021-12-31","value":-45179200000,"profit":false},{"date":"2022-12-31","value":-56181400000,"profit":false},{"date":"2023-12-31","value":-45554100000,"profit":false},{"date":"2024-12-31","value":-27876300000,"profit":false}]
Total Non-Operating Income/Expense(88.66M)64.63M(59.06M)(45.81M)(145.62M)[{"date":"2020-12-31","value":-137.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-91.39,"profit":false},{"date":"2023-12-31","value":-70.88,"profit":false},{"date":"2024-12-31","value":-225.32,"profit":false}]
Pre-Tax Income(419.17M)(383.94M)(577.82M)(474.14M)(373.24M)[{"date":"2020-12-31","value":-41917400000,"profit":false},{"date":"2021-12-31","value":-38394400000,"profit":false},{"date":"2022-12-31","value":-57781700000,"profit":false},{"date":"2023-12-31","value":-47414400000,"profit":false},{"date":"2024-12-31","value":-37324100000,"profit":false}]
Income Taxes(219.00K)(367.00K)5.38M7.30M4.84M[{"date":"2020-12-31","value":-3,"profit":false},{"date":"2021-12-31","value":-5.03,"profit":false},{"date":"2022-12-31","value":73.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":66.32,"profit":true}]
Income After Taxes(418.95M)(383.58M)(583.19M)(481.45M)(378.08M)[{"date":"2020-12-31","value":-41895500000,"profit":false},{"date":"2021-12-31","value":-38357700000,"profit":false},{"date":"2022-12-31","value":-58319400000,"profit":false},{"date":"2023-12-31","value":-48144700000,"profit":false},{"date":"2024-12-31","value":-37808400000,"profit":false}]
Income From Continuous Operations(418.95M)(383.58M)(583.19M)(481.45M)(378.08M)[{"date":"2020-12-31","value":-41895500000,"profit":false},{"date":"2021-12-31","value":-38357700000,"profit":false},{"date":"2022-12-31","value":-58319400000,"profit":false},{"date":"2023-12-31","value":-48144700000,"profit":false},{"date":"2024-12-31","value":-37808400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(418.95M)(383.58M)(583.19M)(481.45M)(378.08M)[{"date":"2020-12-31","value":-41895500000,"profit":false},{"date":"2021-12-31","value":-38357700000,"profit":false},{"date":"2022-12-31","value":-58319400000,"profit":false},{"date":"2023-12-31","value":-48144700000,"profit":false},{"date":"2024-12-31","value":-37808400000,"profit":false}]
EPS (Diluted)(8.24)(7.01)(10.40)(8.56)(6.77)[{"date":"2020-12-31","value":-824,"profit":false},{"date":"2021-12-31","value":-701,"profit":false},{"date":"2022-12-31","value":-1040,"profit":false},{"date":"2023-12-31","value":-856,"profit":false},{"date":"2024-12-31","value":-677,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ASND
Cash Ratio 0.62
Current Ratio 1.17
Quick Ratio 0.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ASND
ROA (LTM) -17.38%
ROE (LTM) -818.43%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ASND
Debt Ratio Lower is generally better. Negative is bad. 1.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.09

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ASND
Trailing PE NM
Forward PE NM
P/S (TTM) 27.14
P/B 14.55
Price/FCF NM
EV/R 24.78
EV/Ebitda NM

FAQs

What is Ascendis Pharma AS share price today?

Ascendis Pharma AS (ASND) share price today is $164.15

Can Indians buy Ascendis Pharma AS shares?

Yes, Indians can buy shares of Ascendis Pharma AS (ASND) on Vested. To buy Ascendis Pharma AS from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ASND stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ascendis Pharma AS be purchased?

Yes, you can purchase fractional shares of Ascendis Pharma AS (ASND) via the Vested app. You can start investing in Ascendis Pharma AS (ASND) with a minimum investment of $1.

How to invest in Ascendis Pharma AS shares from India?

You can invest in shares of Ascendis Pharma AS (ASND) via Vested in three simple steps:

  • Click on Sign Up or Invest in ASND stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ascendis Pharma AS shares
What is Ascendis Pharma AS 52-week high and low stock price?

The 52-week high price of Ascendis Pharma AS (ASND) is $169.37. The 52-week low price of Ascendis Pharma AS (ASND) is $111.09.

What is Ascendis Pharma AS price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ascendis Pharma AS (ASND) is 14.55

What is the Market Cap of Ascendis Pharma AS?

The market capitalization of Ascendis Pharma AS (ASND) is $9.69B

What is Ascendis Pharma AS’s stock symbol?

The stock symbol (or ticker) of Ascendis Pharma AS is ASND

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top